GoDNA™ Platform

About GoDx

GoDx is a private, pre-revenue diagnostics company developing point-of-care (POC) molecular tests for infectious diseases, starting with gastrointestinal pathogens and associated antimicrobial resistance (AMR) genes. Its proprietary technology platform aims to enable direct-from-sample, culture-free nucleic acid detection with rapid turnaround, targeting use in clinics, urgent care, and public health settings. The company has secured non-dilutive grant funding, achieved key regulatory milestones like a CLIA waiver, and gained strategic positioning through acceptance into BARDA's Rapid Response Partnership Vehicle (RRPV).

Therapeutic Areas